Last reviewed · How we verify
Parenteral Insulin
Parenteral insulin replaces or supplements the body's own insulin to regulate blood glucose by promoting glucose uptake into cells and storage as glycogen.
Parenteral insulin replaces or supplements the body's own insulin to regulate blood glucose by promoting glucose uptake into cells and storage as glycogen. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus (when oral agents are insufficient).
At a glance
| Generic name | Parenteral Insulin |
|---|---|
| Sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Drug class | Insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Insulin is a hormone that binds to insulin receptors on cell surfaces, facilitating glucose transport into muscle, fat, and liver cells. This reduces blood glucose levels and promotes anabolic metabolism. Parenteral (injected) insulin is used when the pancreas cannot produce sufficient endogenous insulin, as in type 1 diabetes or advanced type 2 diabetes.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus (when oral agents are insufficient)
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
- Allergic reactions
Key clinical trials
- Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss (PHASE2)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Protocolized Reduction of Non-resuscitation Fluids Versus Usual Care in Septic Shock Patients (NA)
- To Evaluate the Change in Glucose Parameters in Adult Patients With Type 1 or Type 2 Diabetes From Europe Using the iCan o3 CGM System for 60 Days Period (NA)
- DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes (PHASE4)
- Efficacy of Microneedling With Hyaluronic Acid Injection for Gingival Augmentation in Thin Gingival Phenotype (NA)
- Melatonin Loaded in Injectable Platelet-Rich Fibrin in the Management Periodontitis (PHASE4)
- Defining the Human Insulin Resistance Molecular Network; SIGNATURE (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: